Bionano Genomics Symposium Draws 1,000+ Attendees from 70 Countries for OGM Advances
Bionano Genomics hosted Day 1 of its Symposium 2026 with nine presentations showing optical genome mapping’s improved detection of structural variants in leukemias, lymphomas and multiple myeloma. Over 1,000 attendees from 70 countries reviewed data demonstrating OGM’s potential to replace traditional cytogenetics and deepen clinical research workflows.
1. Symposium Attendance and Scope
Bionano Genomics kicked off Day 1 of its 2026 Symposium with over 1,000 virtual attendees representing 70 countries, marking its largest event dedicated to optical genome mapping this year. The opening session highlighted OGM applications for blood and lymphoid cancers and set the stage for in-depth technical presentations.
2. Key OGM Presentation Highlights
Nine experts from leading centers such as MD Anderson, Augusta University and KU Leuven showcased OGM’s high concordance with karyotyping, FISH and NGS while demonstrating improved resolution of complex structural variants. Case studies included cryptic rearrangement detection in chronic lymphocytic leukemia, pathogenic aberration profiling in non-Hodgkin lymphoma and streamlined multiple myeloma workflows.
3. Strategic Implications for Bionano
Panelists emphasized integration of OGM and next-generation sequencing data within VIA software for comprehensive cytogenomic analysis, underscoring OGM’s role in modern research workflows. The global adoption trends and positive performance in clinical research signal potential growth in Bionano Genomics’ market penetration and revenue streams.